We are live on ! Find out more
CLRB icon

Cellectar Biosciences
CLRB

9 hedge funds and large institutions have $961K invested in Cellectar Biosciences in 2016 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

58,733% more capital inflows, than outflows

Capital inflows: $1.18M | Capital outflows: $2K

80% more funds holding

Funds holding: 5 → 9 (+4)

4.89% more ownership

Funds ownership: 4.24% → 9.12% (+4.9%)

Holders
9
Holders Change
+4
Holders Change %
+80%
% of All Funds
0.22%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
3
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
+$586K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$266K
3
Virtu KCG Holdings
Virtu KCG Holdings
New York
+$184K
4
Morgan Stanley
Morgan Stanley
New York
+$54.2K
5
Vanguard Group
Vanguard Group
Pennsylvania
+$48.8K

Top Sellers

Rank Fund Capital Flow
1
Tower Research Capital (TRC)
Tower Research Capital (TRC)
New York
-$2K

CLRB Hedge Fund Activity: Q4 2016 in Review

9 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in Cellectar Biosciences (CLRB) for Q4 2016, worth a combined $961K — up 171% from $354K a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new CLRB positions and 0 closed out — a net gain of 4 holders — while 3 added to existing stakes and 0 trimmed.

The largest buyer was Sabby Management, opening a new position worth an estimated $586K. The largest seller was Tower Research Capital (TRC), cutting an estimated $2K.

  • 9 institutional investors held Cellectar Biosciences (CLRB) as of Q4 2016, up from 5 in Q3 2016.
  • Funds reported $961K of Cellectar Biosciences stock for Q4 2016, up 171% quarter-over-quarter.
  • 4 funds opened new Cellectar Biosciences positions in Q4 2016 and 0 closed out, a net change of +4 holders.
  • The largest Cellectar Biosciences buyer in Q4 2016 was Sabby Management, an estimated $586K added.
  • The largest Cellectar Biosciences seller in Q4 2016 was Tower Research Capital (TRC), an estimated $2K sold.

Based on aggregated 13F filings for Q4 2016.